



Curriculum Vitae Europass

Dr Francesco Izzo

Informazioni personali

Nome(i) / Cognome(i) Francesco Izzo
Indirizzo(i) Via Posillipo 299, 80123, Napoli
Telefono(i) 081/5903627
Fax 081/5903843
E-mail f.izzo@istitutotumori.na.it
Cittadinanza Italiana - CF ZZIFNC65E06F839E
Data di nascita 06/05/1965
Sesso Maschile

Occupazione desiderata/Settore professionale Direttore Struttura Complessa di Chirurgia Oncologica Addominale ad indirizzo Epatobiliare Istituto Tumori di Napoli, Fondazione "G. Pascale"

Esperienza professionale

Date Gennaio 2013
Lavoro o posizione ricoperti Direttore della Struttura Complessa di Chirurgia Oncologica Addominale ad indirizzo Epatobiliare, dell'Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Fondazione G.Pascale

2008/2012
Dirigente Responsabile della SSD Chirurgia Fegato nel Dipartimento Esofago – Gastro –Epatobilio - Pancreatico e Responsabile del Gruppo Operativo dei Tumori Epatobiliari, "LIE" (Linee Interdipartimentali Editor), dell'Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Fondazione Giovanni Pascale.

1991/oggi
Ricercatore responsabile e/o associato nell'ambito dei progetti di ricerca area "Apparato Digerente", afferenti alla ricerca corrente dell'Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli;

1990/1993
Ricercatore incaricato: "Progetto ricerche in oncologia", presso l'Istituto Superiore di Sanità (I.S.S.);

1994/oggi
Professore a Contratto (Visiting Professor of Surgery) presso l'University of Texas "M.D. Anderson Cancer Center" con licenza per eseguire interventi chirurgici e didattica rilasciata dal Texas State Board of Medical Examiners, in data 28 giugno 1994, n. 26245.

2001/oggi
Professore a Contratto per l'Insegnamento di "Chirurgia Generale", nell'ambito del Diploma di Laurea per Infermiere, presso la Seconda Università degli Studi di Napoli;

2005/oggi
Membro dell'Editorial Board, in the Hepatic and Pancreatic Tumors sections of the "Annals of Surgical Oncology", the official Journal of the Society of Surgical Oncology;

2007/oggi
Membro del International Committee SSO (Society of Surgical Oncology);

2008/oggi
Membro del Consiglio Direttivo SITILO
(Società Italiana di Terapie Integrate Locoregionali in Oncologia);

2008/oggi
Member of the ASCO International Affairs Committee;

2009/oggi
Member from 2010 of the Editorial Board of World Journal of Hepatology;

2011/oggi
Membro del Consiglio Direttivo della Società Italiana di Chirurgia Oncologica (SICO);

Istruzione e formazione

Date 31/07/1989
Titolo della qualifica rilasciata Laurea in Medicina e Chirurgia
Ila Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli, Federico II°

1990/1994
Specializzazione in Chirurgia d'Urgenza e Pronto Soccorso
Ila Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli, Federico II°

30/07/1995
Fellowship in Surgical Oncology
University of Texas, M.D.Anderson Cancer Center, Houston

26/03/1999
Master in Manager della Sanità e Direttore Generale di A.S.L.
Accademia Italiana delle Ricerche, Napoli, Italia

Capacità e competenze personali

Madrelingua(e) ITALIANO

Altra(e) lingua(e)

Autovalutazione

Livello europeo (*)

INGLESE

FRANCESE

SPAGNOLO

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
ECCELLENTE	ECCELLENTE	ECCELLENTE	ECCELLENTE	ECCELLENTE
BUONA	BUONA	BUONA	BUONA	SUFFICIENTE
BUONA	BUONA	BUONA	BUONA	SUFFICIENTE

Ulteriori informazioni

PUBBLICAZIONI EDITORIALI:

- Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Radiol Med 2015; ():
- The Cytokine Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.
PLoS One 2015; 10 (7): e0134594.
- Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth.
Infect Agent Cancer 2015; 10 (): 22.
- Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases.
Int J Surg 2015; 21 Suppl 1 (): S78-82.
- The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.
Abdom Imaging 2015; 40 (7): 2364-71.
- Morphine Promotes Tumor Angiogenesis and Increases Breast Cancer Progression.
Biomed Res Int 2015; 2015 (): 161508.
- Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases.
PLoS One 2015; 10 (5): e0128849.
- Low vitamin D levels are associated with the presence of serum cryoglobulins in patients with chronic HCV infection.
In Vivo 2015 May-Jun; 29 (3): 399-404.
- Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.
Cancer Immunol Immunother 2015; 64 (10): 1305-14.
- Percutaneous ablation therapy of hepatocellular carcinoma with irreversible electroporation: MRI findings.
AJR Am J Roentgenol 2015; 204 (5): 1000-7.
- Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments.
Infect Agent Cancer 2015; 10 (): 11.
- Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer.
Biomed Res Int 2015; 2015 (): 878134.
- Prognostic role of the CDKN1B V109G polymorphism in multiple endocrine neoplasia type 1.
J Cell Mol Med 2015; 19 (7): 1735-41.
- An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma.
Infect Agent Cancer 2015; 10 (): 9.
- Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.
PLoS One 2015; 10 (2): e0117420.
- The role of hepatic resection in the treatment of hepatocellular cancer.
Hepatology 2015; 62 (2): 440-51.
- Hepatocellular carcinoma: preclinical data on a dual-lumen catheter kit for fibrin sealant infusion following loco-regional treatments.
Infect Agent Cancer 2014; 9 (1): 39.
- CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.
Cell Mol Immunol 2015; 12 (4): 474-82.
- The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.
Infect Agent Cancer 2014; 9 (): 27.
- Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience.
Acta Radiol 2015; 56 (2): 133-42.
- Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection.
Biomed Res Int 2014; 2014 (): 710642
- Hepatocellular carcinoma: preclinical data on a dual-lumen catheter kit for fibrin sealant infusion following loco-regional treatments
Infect Agent Cancer 2014; 9 (1): 39.
- CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.
Cell Mol Immunol 2014; (): .
- The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets
Infect Agent Cancer 2014; 9 (): 27.
- Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection.
Biomed Res Int 2014; 2014 (): 710642.
- Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Catalano O, Izzo F, Vallone P, Sandomenico F, Albino V, Nunziata A, Fusco R, Petrillo A
Acta Radiol February 12, 2014
- Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan-Experience of High Volume Oncologic Institute.
Gastroenterol Res Pract 2013; 2013 (): 469097.
- Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab.
J Nucl Med 2013; 54 (12): 2062-9.
- Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol 2013; 59 (4): 753-61.
- Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients
HPB (Oxford) 2013; 15 (12): 985-90.
- Mutations in TP53, CTNFB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Genomics 2013; 102 (2): 74-83.
- Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma.
Oncol Rep 2013; 29 (6): 2163-8.
- Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Br J Cancer 2013; 108 (8): 1566-70.
- Can hepatocellular carcinoma (HCC) produce unconventional metastases? Four cases of extrahepatic HCC.
Tumori 2013 Jan-Feb 99 (1): e19-23.
- Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity
radiosensitivity after radioembolization with yttrium-90 resin microspheres.

J Exp Clin Cancer Res 2013; 32 (1): 13.

Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013; 8 (2): e56153.

Identification and sequence analysis of a novel human leukocyte antigen allele B*51:141. Tissue Antigens 2013; 81 (1): 55-6.

Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013; 108 (1): 222-8.

Upper limb function and quality of life in breast cancer related lymphedema: a cross-sectional study. Eur J Phys Rehabil Med 2013; 49 (5): 665-73.

Oncolytic virus therapies. Pharm Pat Anal. 2012; 1 (5): 621-7.

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012; 3 (1): e259.

Metabolic syndrome is also a risk factor for primary liver cancer in patients younger than 65 years of age? Hepatology 2011; 54 (6): 2277-8.

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54 (3): 868-78.

Induction of argininosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep 2011; 25 (6): 1495-502.

Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. Oncol Rep 2011; 25 (4): 899-904.

Metabolic syndrome increases the risk of primary liver cancer in the united states: a study in the SEER-medicare database. Hepatology. 2011 Sep 6. doi: 10.1002/hep.24643

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011 Aug 15;6:13

Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011 May 26. doi: 10.1002/hep.24451. [Epub ahead of print]

Induction of argininosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep. 2011 Jun;25(6):1495-502.

Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. Oncol Rep. 2011 Apr;25(4):899-904.

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010 Jul 27;103(3):324-31. Epub 2010 Jul 13

Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw. 2010 Jun 1;21(2):99-104. Epub 2010 May 18

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol. 2010 May 1;28(13):2220-6. Epub 2010 Mar 29.

Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol. 2010 Jul;66(2):209-18. Epub 2010 Mar 24. Review.

HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 2010 Mar;134(3):237-50. Epub 2009 Nov 11. Review.

Case report: appearance of an intestinal metastasis from intrahepatic cholangiocarcinoma occurring 5 years after resection of the primary tumor. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):892-4.

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med. 2009 Oct 12;7:85.

Can hepatocellular cancer screening increase the proportion of long-term survivors? Hepatogastroenterology. 2009 Jul-Aug;56(93):1152-6.

Management of colorectal liver metastases in patients with peritoneal carcinomatosis. J Surg Oncol. 2009 Sep 15;100(4):345-7. Review.

An inaccurate literature review and citation. Radiology. 2008 Mar;246(3):982. No abstract available.

Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. Curr Med Res Opin. 2008 Apr;24(4):1011-5. Epub 2008 Feb 19.

Nutrients intake and the risk of hepatocellular carcinoma in Italy. Eur J Cancer. 2007 Nov;43(16):2381-7. Epub 2007 Aug 23

Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer. 2007 Apr 1;120(7):1555-9.

A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo. 2006 Nov-Dec;20(6A):711-4.

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol. 2007 Jan;22(1):86-91.

Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy. Int J Cancer. 2006 Dec 15;119(12):2916-21.

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Anticancer Drugs. 2006 Sep;17(8):985-92.

Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol. 2006 Sep;59(3):243-9. Epub 2006 Aug 17.

Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):683-9.

Combined ethanol injection therapy and radiofrequency ablation therapy in percutaneous treatment of hepatocellular carcinoma

larger than 4 cm.
Cardiovasc Intervent Radiol. 2006 Jul-Aug;29(4):544-51.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
J Clin Oncol. 2005 Oct 20;23(30):7660-8. Erratum in: J Clin Oncol. 2006 Aug 20;24(24):4047.
An assessment of hepatitis C virus infection among health-care workers of the National Cancer Institute of Naples, Southern Italy.
Eur J Public Health. 2005 Oct;15(5):467-9. Epub 2005 Jul 21.
A prospective evaluation of ultrasound-directed transparenchymal vascular control with linear cutting staplers in major hepatic resections.
Am J Surg. 2005 Jul;190(1):23-9.
Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
Ann Surg Oncol. 2005 Aug;12(8):616-28. Epub 2005 Jun 20.
The rising health and economic burden of chronic hepatitis C.
J Hepatol. 2004 Aug;41(2):353-4; author reply 354-5. No abstract available.
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
J Clin Oncol. 2004 May 15;22(10):1815-22.
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients.
Ann Surg. 2004 Apr;239(4):450-8.
IF TOTALE: 577,798 ; H-INDEX: 33; Numero totale di citazioni (Sum of the times cited): 4.187; Banca Dati utilizzata: SCOPUS

E' autore di oltre 200 pubblicazioni in esteso ,su riviste internazionali con "peer review" e 20 monografie e capitoli e libri.

SOCIETA' PROFESSIONALI:


Associazione di Studio per la Chirurgia generale (A.S.C.G.) dal 1987.
Società Polispecialistica Italiana dei Giovani Chirurghi (SPIGC) dal 1987.
Società Italiana di Chirurgia d'Urgenza (S.I.C.U.) dal 1989.
Società Italiana di Fisiopatologia Chirurgica (S.I.FI.P.A.C.) dal 1989.
Società Italiana di Prevenzione e Diagnosi dei Tumori (S.I.P.D.T.) dal 1990.
Società Italiana di Chirurgia Oncologica (S.I.C.O.) dal 1990.
Associazione Chirurghi Ospedalieri Italiani (A.C.O.I.) dal 1990.
European Society of Surgical Oncology (ESSO) dal 1990.
Società Italiana di Chirurgia (S.I.C.) dal 1993.
Society of Surgical Oncology (S.S.O.) U.S.A. dal 1993.
Società Italiana di Terapie Locoregionale in Oncologia (SITILO) dal 1995.
M.E.N.S., Medical European Network Society dal 1997.
World Federation of Surgical Oncology (WFSOS) dal 1998.
Associazione Italiana Malati di Cancro (AIMaC) dal 1998.
American Society of Clinical Oncology (ASCO) dal 1999.

RICERCA CORRENTE:

Ricerca clinico-scientifica applicata alla Chirurgia epato-bilio-pancreatica ed apparato digerente.
Il suo interesse scientifico, si è sviluppato dalle ricerche in vitro ed in vivo, sulle linee cellulari di tumore epatocellulare e coloretale, alle metodiche chirurgiche integrate e alle nuove terapie locoregionali e genetiche per il trattamento dei tumori epatobiliari. Inoltre ha avviato alcuni studi di screening regionali sui portatori di epatite virale, con lo scopo di valutare la compliance, l'epidemiologia e alcune caratteristiche ambientali e genetiche di questa popolazione per selezionare i soggetti ad alto rischio d'insorgenza di tumori primitivi del fegato

Il sottoscritto dichiara altresì di concedere l'autorizzazione al trattamento dei dati personali ai fini ECM (pubblicazione del curriculum vitae nella banca Dati del sito ECM e trasmissione dei dati personali alla Commissione ECM), ai sensi del D.L. 30 giugno 2003, n. 196).

Firma



Napoli, 10/01/2017